Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1/2 1

Status

Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 2Carcinoma, Hepatocellular 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Nivolumab 24Pemetrexed 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Capecitabine 14Fluorouracil 14Docetaxel 13atezolizumab 13Lenalidomide 12Trastuzumab 12durvalumab 12trastuzumab deruxtecan 12Cytarabine 11daratumumab 11130-nm albumin-bound paclitaxel 10Bevacizumab 10Bortezomib 10Prednisone 10olaparib 10Doxorubicin 9Crizotinib 8Oxaliplatin 8venetoclax 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has announcements × lenvatinib × Clear all
NCT04039607 2026-04-06

CheckMate 9DW

Bristol-Myers Squibb

Phase 3 Active not recruiting
732 enrolled 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT03517449 2026-03-19

MK-3475-775

Eisai Inc.

Phase 3 Completed
827 enrolled 34 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting
1,069 enrolled 12 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
357 enrolled 28 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Phase 3 Completed
954 enrolled 19 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡